What is SpeechVive?
SpeechVive offers a wearable speech device specifically engineered for patients diagnosed with Parkinson's disease. This technology provides immediate enhancements in speech volume and clarity, serving as a viable alternative to intensive therapy sessions. The device's approval by Medicare and various insurance plans ensures broad accessibility for a wide patient demographic. By enabling users to regain their voice, SpeechVive significantly improves their quality of life and facilitates more comfortable social interactions. Clinicians can leverage SpeechVive as an effective tool, delivering rapid positive outcomes for their patients.
How much funding has SpeechVive raised?
SpeechVive has raised a total of $727K across 2 funding rounds:
Series A
$700K
Debt
$27K
Series A (2014): $700K with participation from Ambassador Enterprises, LLC
Debt (2021): $27K led by PPP
Key Investors in SpeechVive
Ambassador Enterprises, LLC
Ambassador Enterprises is a private equity firm focused on creating lasting positive impact through investments that yield eternal, cultural, and financial returns. They partner with leaders and organizations dedicated to community betterment.
What's next for SpeechVive?
The recent substantial expansion capital infusion positions SpeechVive for significant growth and market penetration. This enterprise-level funding is expected to fuel advancements in product development, enhance manufacturing capabilities, and broaden the company's outreach to healthcare providers and patient communities. Strategic investments in these areas will likely solidify SpeechVive's market leadership in wearable speech solutions for neurodegenerative conditions.
See full SpeechVive company page
